Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ampicillin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 1.00 |
| ▸ | RECQL | P46063 | 4/20 | 1.00 |
| ▸ | HPGD | P15428 | 4/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | TEK | Q02763 | 1/20 | 1.00 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 6/20 | 0.98 |
| ▸ | TSHR | P16473 | 2/20 | 0.98 |
| ▸ | RARB | P10826 | 1/20 | 0.84 |
| ▸ | RARG | P13631 | 1/20 | 0.84 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.84 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.84 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.84 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.82 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.82 |
| ▸ | GLA | P06280 | 1/20 | 0.82 |
| ▸ | BLM | P54132 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ampicillin SCHEMBL14148474 | 1.00 | KDM4E (1.00) | KDM4ERECQLHPGDTDP1POLB | |
| Ampicillin SCHEMBL11985596 | 1.00 | KDM4E (1.00) | KDM4ERECQLHPGDTDP1POLB | |
| Ampicillin SCHEMBL9528765 | 1.00 | KDM4E (1.00) | KDM4ERECQLHPGDTDP1POLB | |
| Ampicillin SCHEMBL2282070 | 1.00 | KDM4E (1.00) | KDM4ERECQLHPGDTDP1POLB | |
| Ampicillin SCHEMBL13014516 | 1.00 | KDM4E (1.00) | KDM4ERECQLHPGDTDP1POLB | |
| Ampicillin SCHEMBL24312533 | 1.00 | KDM4E (1.00) | KDM4ERECQLHPGDTDP1POLB | |
| Ampicillin SCHEMBL13240124 | 1.00 | KDM4E (1.00) | KDM4ERECQLHPGDTDP1POLB | |
| Ampicillin SCHEMBL15577318 | 1.00 | KDM4E (1.00) | KDM4ERECQLHPGDTDP1POLB | |
| Ampicillin SCHEMBL22380861 | 1.00 | KDM4E (1.00) | KDM4ERECQLHPGDTDP1POLB | |
| Ampicillin SCHEMBL13007617 | 1.00 | KDM4E (1.00) | KDM4ERECQLHPGDTDP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 214 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3498717-B1 | COMPOSITION FOR HARDENING SOFT TISSUE | CATHOLIC UNIV KOREA IND ACADEMIC COOPERATION FOUNDATION (KR) | 2022-05-04 | — | — | EP | claimed |
| US-20200339601-A1 | Composition for Hardening Soft Tissue | THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2020-10-29 | — | — | US | claimed |
| US-10745417-B2 | Composition for hardening soft tissue | THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2020-08-18 | — | — | US | claimed |
| US-20190315770-A1 | COMPOSITION FOR HARDENING SOFT TISSUE | SONY SEMICONDUCTOR SOLUTIONS CORPORATION (JP) | 2019-10-17 | — | — | US | claimed |
| EP-3498717-A1 | COMPOSITION FOR HARDENING SOFT TISSUE | The Catholic University of Korea Industry-Academic Cooperation Foundation (KR) | 2019-06-19 | — | — | EP | claimed |
| WO-2018030840-A1 | COMPOSITION FOR HARDENING SOFT TISSUE | 가톨릭대학교 산학협력단 | 2018-02-15 | — | — | WO | claimed |
| WO-2010078258-A1 | COMPOUNDS COMPRISING TWO OR MORE BIOLOGICALLY FUNCTIONAL IONS AND METHOD OF TREATING PARKINSON'S DISEASE | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2010-07-08 | — | — | WO | claimed |
| EP-0294789-B1 | Process for preparing 6-/D(-)-Alpha-(4-ethyl-2,3-dioxo-1-piperazine-carboxamido)-phenylacetamido/pennicillanic acid | KRKA TOVARNA ZDRAVIL (YU) | 1994-10-12 | — | — | EP | claimed |
| EP-0317484-B1 | N,N'-carboxyl-bis-(4-ethyl-2,3-dioxo)-piperazine, process for the preparation thereof and use thereof | GEMA SA (ES) | 1994-03-16 | — | — | EP | claimed |
| US-5015736-A | Piperazine intermediates | GEMA, S.A. (ES) | 1991-05-14 | — | — | US | claimed |
| EP-0008917-B1 | PENAM-3-CARBOXYLIC ACID 1,1-DIOXIDES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | PFIZER INC. (US) | 1982-11-24 | — | — | EP | claimed |
| EP-0014651-B1 | TALAMPICILLIN 2-METHOXYPHENOXY ACETATE, PROCESS FOR ITS PREPARATION AND MEDICAMENTS CONTAINING IT | SANOFI S.A. (FR) | 1982-08-04 | — | — | EP | claimed |
| US-4293560-A | BACTERICIDES, ANTIBIOTICS | C M INDUSTRIES (FR) | 1981-10-06 | — | — | US | claimed |
| US-4287181-A | TO ENHANCE THE EFFECTIVENESS OF B-LACTAM ANTIBIOTICS | PFIZER INC. (US) | 1981-09-01 | — | — | US | claimed |
| US-4260598-A | ADMINISTERING 6-AMINOPENICILLANIC ACID 1,1-DIOXIDE OR ESTERS THEREOF | PFIZER INC. (US) | 1981-04-07 | — | — | US | claimed |
| US-4256733-A | Acetoxymethyl penam compounds as β-lactamase inhibitors | PFIZER INC. (US) | 1981-03-17 | — | — | US | claimed |
| US-4241050-A | Penam 1,1-dioxides as beta-lactamase inhibitors | PFIZER INC. (US) | 1980-12-23 | — | — | US | claimed |
| US-4234579-A | Penicillanic acid 1,1-dioxides as β-lactamase inhibitors | PFIZER INC. (US) | 1980-11-18 | — | — | US | claimed |
| EP-0008917-A1 | Penam-3-carboxylic acid 1,1-dioxides, process for their preparation and pharmaceutical compositions | PFIZER INC. (US) | 1980-03-19 | — | — | EP | claimed |
| US-3941773-A | CRYSTALLINE | BRISTOL-MYERS COMPANY (US) | 1976-03-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339601-A1 | Composition for Hardening Soft Tissue | PNLIP, AMY2A, RNASE1 | KDM4E 2054/4885RECQL 890/4885HPGD 115/4885 |
| US-20190315770-A1 | COMPOSITION FOR HARDENING SOFT TISSUE | PNLIP, AMY2A, RNASE1 | KDM4E 2054/4885RECQL 890/4885HPGD 115/4885 |
| US-10745417-B2 | Composition for hardening soft tissue | PNLIP, AMY2A, RNASE1 | KDM4E 2054/4885RECQL 890/4885HPGD 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.